Lineage Cell Therapeutics
LCTX
112 hedge funds and large institutions have $149M invested in Lineage Cell Therapeutics in 2025 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 33 reducing their positions, and 34 closing their positions.
665% more call options, than puts
Call options by funds: $650K | Put options by funds: $85K
68% more capital invested
Capital invested by funds: $88.4M → $149M (+$60.2M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.31% less ownership
Funds ownership: 42.82% → 38.5% (-4.3%)
13% less funds holding
Funds holding: 129 → 112 (-17)
30% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 33
50% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$620K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$523K |
| 3 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$483K |
| 4 |
QC
Quadrature Capital
London,
United Kingdom
|
+$212K |
| 5 |
Morgan Stanley
New York
|
+$200K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$6.16M |
| 2 |
Jane Street
New York
|
-$1.61M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$471K |
| 4 |
Squarepoint
New York
|
-$464K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$429K |
LCTX Hedge Fund Activity: Q3 2025 in Review
112 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2025, worth a combined $149M — up 68% from $88.4M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LCTX and 17 opened new positions — a net loss of 17 holders — while 33 trimmed existing stakes and 23 added.
The largest buyer was Vanguard Group, adding an estimated $620K. The largest seller was Defender Capital, exiting entirely with an estimated $6.16M sold.
- 112 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2025, down from 129 in Q2 2025.
- Funds reported $149M of Lineage Cell Therapeutics stock for Q3 2025, up 68% quarter-over-quarter.
- 17 funds opened new Lineage Cell Therapeutics positions in Q3 2025 and 34 closed out, a net change of -17 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2025 was Vanguard Group, an estimated $620K added.
- The largest Lineage Cell Therapeutics seller in Q3 2025 was Defender Capital, an estimated $6.16M sold.
Based on aggregated 13F filings for Q3 2025.